Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Qihan will leverage its proprietary genome editing technology to reduce the immunogenicity of human stem cells, thus limiting their ability to provoke an immune response.
Lead Product(s): Allogeneic cell therapies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020